Björn Andréasson

3.6k total citations
70 papers, 1.6k citations indexed

About

Björn Andréasson is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Björn Andréasson has authored 70 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Genetics, 47 papers in Hematology and 23 papers in Molecular Biology. Recurrent topics in Björn Andréasson's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (58 papers), Acute Myeloid Leukemia Research (18 papers) and Kruppel-like factors research (18 papers). Björn Andréasson is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (58 papers), Acute Myeloid Leukemia Research (18 papers) and Kruppel-like factors research (18 papers). Björn Andréasson collaborates with scholars based in Sweden, United States and Italy. Björn Andréasson's co-authors include Peter Johansson, Jack Kutti, Jan Samuelsson, Gunnar Birgegård, Ruben A. Mesa, Claire Harrison, Alessandro Rambaldi, Robyn M. Scherber, Tiziano Barbui and Malin Hultcrantz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Björn Andréasson

68 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Björn Andréasson Sweden 22 1.4k 1.1k 792 601 129 70 1.6k
Marina Kremyanskaya United States 18 672 0.5× 625 0.6× 404 0.5× 234 0.4× 68 0.5× 91 914
Lynda Foltz Canada 15 611 0.4× 479 0.4× 342 0.4× 246 0.4× 82 0.6× 50 824
Lucia Malabarba Italy 10 525 0.4× 411 0.4× 309 0.4× 235 0.4× 54 0.4× 12 685
Anthony K. Mills Australia 14 727 0.5× 892 0.8× 126 0.2× 442 0.7× 248 1.9× 41 1.1k
Salman Fazal United States 12 320 0.2× 394 0.4× 192 0.2× 121 0.2× 140 1.1× 51 653
Catherine Cargo United Kingdom 11 378 0.3× 416 0.4× 134 0.2× 109 0.2× 49 0.4× 28 607
Najla Al Ali United States 15 532 0.4× 854 0.8× 306 0.4× 50 0.1× 113 0.9× 112 930
Luigiana Luciano Italy 14 294 0.2× 430 0.4× 116 0.1× 154 0.3× 80 0.6× 32 622
Yue‐Yun Lai China 14 256 0.2× 542 0.5× 196 0.2× 101 0.2× 119 0.9× 79 693
Jolanta B. Perz Germany 14 154 0.1× 396 0.4× 402 0.5× 141 0.2× 154 1.2× 27 795

Countries citing papers authored by Björn Andréasson

Since Specialization
Citations

This map shows the geographic impact of Björn Andréasson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Björn Andréasson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Björn Andréasson more than expected).

Fields of papers citing papers by Björn Andréasson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Björn Andréasson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Björn Andréasson. The network helps show where Björn Andréasson may publish in the future.

Co-authorship network of co-authors of Björn Andréasson

This figure shows the co-authorship network connecting the top 25 collaborators of Björn Andréasson. A scholar is included among the top collaborators of Björn Andréasson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Björn Andréasson. Björn Andréasson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guglielmelli, Paola, Arianna Ghirardi, Alessandra Carobbio, et al.. (2025). Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry. HemaSphere. 9(2). e70072–e70072.
2.
Andréasson, Björn, et al.. (2023). Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study. European Journal Of Haematology. 110(6). 608–617. 2 indexed citations
3.
Adamsson, Jenni, Peter Johansson, Staffan Nilsson, et al.. (2023). The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis. Frontiers in Oncology. 13. 1190305–1190305. 1 indexed citations
4.
Einarsdottir, Sigrun, Tomas Bergström, Berit Johansson, et al.. (2021). Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation. Vaccine. 39(7). 1035–1038. 3 indexed citations
5.
Guglielmelli, Paola, Arianna Ghirardi, Alessandra Carobbio, et al.. (2021). Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances. 6(2). 373–375. 40 indexed citations
6.
Andréasson, Björn, et al.. (2020). ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patients. British Journal of Haematology. 189(5). 913–919. 12 indexed citations
7.
Hjorth, Martin, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.. (2012). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal Of Haematology. 88(6). 485–496. 41 indexed citations
8.
Gowin, Krisstina, John Samuelson, Claire Harrison, et al.. (2012). Experience with pegylated interferon  -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 97(10). 1570–1573. 68 indexed citations
9.
Björkholm, Magnus, Åsa Rangert Derolf, Malin Hultcrantz, et al.. (2011). Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. Journal of Clinical Oncology. 29(17). 2410–2415. 174 indexed citations
10.
Merup, Mats, Gunnar Birgegård, Lorentz Brinch, et al.. (2011). The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplantation. 47(3). 380–386. 43 indexed citations
11.
Johansson, Peter, Ruben A. Mesa, Robyn M. Scherber, et al.. (2011). Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leukemia & lymphoma. 53(3). 441–444. 41 indexed citations
12.
Ridell, Börje, et al.. (2010). The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. European Journal Of Haematology. 86(2). 148–155. 55 indexed citations
13.
Andréasson, Björn, Eva Löfvenberg, & Jan Westin. (2005). Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. European Journal Of Haematology. 74(6). 489–495. 19 indexed citations
14.
Johansson, Peter, Jack Kutti, Björn Andréasson, et al.. (2004). Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99. Journal of Internal Medicine. 256(2). 161–165. 48 indexed citations
15.
Andréasson, Björn, Birgitta Swolin, & Jack Kutti. (2002). Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. European Journal Of Haematology. 68(4). 189–193. 27 indexed citations
16.
Johansson, Peter, et al.. (2002). On the diagnosis of polycythaemia vera as assessed in the health and medical care in the Västra Götaland region, Sweden. Journal of Internal Medicine. 251(4). 348–354. 7 indexed citations
17.
Andréasson, Björn, Göran Lindstedt, Dick Stockelberg, Hans Wadenvik, & Jack Kutti. (2001). The Relation Between Plasma Thrombopoietin and Erythropoietin Concentrations in Polycythaemia Vera and Essential Thrombocythaemia. Leukemia & lymphoma. 41(5-6). 579–584. 5 indexed citations
18.
Andréasson, Björn, Jan Carneskog, Göran Lindstedt, et al.. (2000). Plasma Erythropoietin Concentrations in Polycythaemia Vera with Special Reference to Myelosuppressive Therapy. Leukemia & lymphoma. 37(1-2). 189–195. 14 indexed citations
19.
Andréasson, Björn, Birgitta Swolin, & Jack Kutti. (2000). Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia. European Journal Of Haematology. 64(3). 188–193. 16 indexed citations
20.
Andréasson, Björn, Erik Wahlström, Staffan Jacobsson, et al.. (1999). The measurement of venous haematocrit in patients with polycythaemia vera. Journal of Internal Medicine. 246(3). 293–297. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Kremyanskaya Breakdown of academic impact, for papers by Lynda Foltz Breakdown of academic impact, for papers by Lucia Malabarba Breakdown of academic impact, for papers by Anthony K. Mills Breakdown of academic impact, for papers by Salman Fazal Breakdown of academic impact, for papers by Catherine Cargo Breakdown of academic impact, for papers by Najla Al Ali Breakdown of academic impact, for papers by Luigiana Luciano Breakdown of academic impact, for papers by Yue‐Yun Lai Breakdown of academic impact, for papers by Jolanta B. Perz
Rankless by CCL
2026